F
Françoise Lejeune
Publications - 51
Citations - 3307
Françoise Lejeune is an academic researcher. The author has contributed to research in topics: Agonist & Serotonin. The author has an hindex of 28, co-authored 51 publications receiving 3218 citations.
Papers
More filters
Journal ArticleDOI
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
Millan Mark,Alain Gobert,Françoise Lejeune,Anne Dekeyne,Adrian Newman-Tancredi,Valérie Pasteau,Jean-Michel Rivet,Didier Cussac +7 more
TL;DR: In contrast to melatonin, agomelatine behaves as an antagonist at 5- HT2B and 5-HT2C receptors: blockade of the latter reinforces frontocortical adrenergic and dopaminergic transmission.
Journal ArticleDOI
Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
Alain P. Gobert,Jean-Michel Rivet,Françoise Lejeune,Adrian Newman-Tancredi,Agnes Adhumeau‐Auclair,Jean-Paul Nicolas,Laetitia Cistarelli,Christophe Melon,Millan Mark +8 more
TL;DR: 5‐HT2C receptors exert a tonic, suppressive influence on the activity of mesocortical — as well as mesolimbic and nigrostriatal — dopaminergic pathways, likely via indirect actions expressed at the level of their cell bodies.
Journal ArticleDOI
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents.
TL;DR: Electrophysiological and dialysis analyses of the complex and reciprocal pattern of autoand heteroreceptor mediated control of dopaminergic, noradrenergic and serotonergic transmission in the FCX provide a framework for an interpretation of the influence of diverse classes of antidepressant agent upon extracellular levels of dopamine, Noradrenaline and serotonin in FCX.
Journal ArticleDOI
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Millan Mark,Adrian Newman-Tancredi,Valérie Audinot,Didier Cussac,Françoise Lejeune,Jean-Paul Nicolas,Francis Cogé,Jean-Pierre Galizzi,Jean A. Boutin,Jean-Michel Rivet,Anne Dekeyne,Alain Gobert +11 more
TL;DR: The α2‐AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine, whereas fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover and enhances striatal dopamine turnover and suppresses striatal turnover of 5‐HT.
Journal ArticleDOI
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
M.J. Millan,Alain Gobert,J. ‐M. Rivet,A. Adhumeau-Auclair,Cussac Didier,Adrian Newman-Tancredi,A. Dekeyne,Jean-Paul Nicolas,Françoise Lejeune +8 more
TL;DR: In contrast to citalopram, mirtazapine reinforces frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission, and reflects antagonist properties at α2A‐AR and 5‐HT2C receptors.